Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Published on January 21, 2014 at 12:08 PM · No Comments

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). The H7N9 strain is of concern due to its pandemic potential. Human cases of this avian-origin influenza strain were first recognized in early 2013.

Vivaldi's LAIV technology platform uses the biology of the influenza nonstructural protein 1 (NS1) to provide a new vaccine approach with the potential for superior efficacy and protection. NS1 is a multifunctional virulence factor of the influenza virus. Vivaldi uses proprietary reverse genetics and plasmid rescue technologies to modify the NS1 gene, generating replication-deficient LAIVs attenuated for safety and able to produce a potent, protective immune response.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post